EASL 2021 Olena Yakobchuk/Shutterstock.comCoronavirusCOVID-19 vaccine responses are weaker in liver transplant patients Conference news bulletinRead our EASL 2021 news bulletin in English, Spanish, Russian, French & Portuguese Professor Rifaat Safadi of Hadassah University Hospital, Jerusalem, speaking at an International Liver Congress 2021 press briefingCoronavirusWeaker COVID-19 vaccine responses seen in people with advanced liver fibrosis infohep news Treatment for hepatocellular carcinoma Immunotherapy plus arterial infusion chemotherapy shows promise for advanced liver cancer Liz Highleyman / 12 July 2021 An experimental immune checkpoint inhibitor plus chemotherapy delivered directly into the hepatic artery in the liver led to good outcomes in people with locally advanced hepatocellular carcinoma (HCC), the most common type of ... Coronavirus Weaker COVID-19 vaccine responses seen in people with advanced liver fibrosis Liz Highleyman / 05 July 2021 Among people with non-alcoholic fatty liver disease (NAFLD), those with more advanced liver fibrosis did not respond as well to the Pfizer-BioNTech COVID-19 vaccine, according to study results presented at the 2021 International ... Experimental treatments for NASH/NAFLD Resmetirom reduces liver fat and fibrosis in people with NASH Liz Highleyman / 01 July 2021 Resmetirom, a thyroid hormone receptor agonist, appeared to reduce liver fat and fibrosis, as determined by biomarkers and non-invasive imaging, in people with non-alcoholic steatohepatitis (NASH), according to a presentation at the 2021 International ... Hepatitis C elimination Peer support improved hepatitis C treatment uptake and completion in England Keith Alcorn / 30 June 2021 Peer support increased hepatitis C treatment initiation and completion in England between 2017 and 2020, an evaluation of a national peer support scheme run by the Hepatitis C Trust has found. ... Screening and testing policy Reflex testing successfully uncovers hidden hepatitis C cases in Scotland Keith Alcorn / 29 June 2021 Automatic viral hepatitis testing of blood samples from patients with abnormal liver function has the potential to identify “hard to reach” people with hepatitis B or C who have no known risk ... NAFLD Food insecurity raises the risk of death in people with fatty liver disease Keith Alcorn / 28 June 2021 Food insecurity – limited or unreliable food supplies due to poverty – was associated with an increased risk of death in US adults with non-alcoholic fatty liver disease (NAFLD) or advanced fibrosis ... Hepatitis D Bulevirtide appears safe and effective for hepatitis D Liz Highleyman / 28 June 2021 The entry inhibitor bulevirtide (Hepcludex) suppressed hepatitis delta viral load and improved liver enzyme levels in a phase III clinical trial, according to late-breaking study results presented this week at the 2021 International Liver ... Coronavirus Advanced cirrhosis or alcohol use disorder raised the risk of COVID-19 death in France Keith Alcorn / 25 June 2021 People with advanced cirrhosis or alcohol use disorder were significantly more likely to die from COVID-19 in France during 2020 compared to the rest of the population, a study of the French ... Coronavirus Antiviral treatments for hepatitis B may reduce severity of COVID-19 or risk of infection Keith Alcorn / 25 June 2021 People taking tenofovir (Viread) as treatment for hepatitis B were significantly less likely to suffer severe COVID-19 or to need mechanical ventilation after admission to hospital than people taking the alternative hepatitis B ... View more > Editors' picks from other sources View more > Other pages in this section Latest news All the news Conference news Email bulletin archive